JP2021119136A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021119136A5 JP2021119136A5 JP2021060013A JP2021060013A JP2021119136A5 JP 2021119136 A5 JP2021119136 A5 JP 2021119136A5 JP 2021060013 A JP2021060013 A JP 2021060013A JP 2021060013 A JP2021060013 A JP 2021060013A JP 2021119136 A5 JP2021119136 A5 JP 2021119136A5
- Authority
- JP
- Japan
- Prior art keywords
- temperature
- disease
- compound
- xrpd
- crystal according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 claims 2
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 claims 2
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000001237 Raman spectrum Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166641.9 | 2015-05-06 | ||
| EP15166641.9A EP3090998A1 (en) | 2015-05-06 | 2015-05-06 | Solid forms |
| JP2017557899A JP7005007B2 (ja) | 2015-05-06 | 2016-05-02 | 固体形態 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557899A Division JP7005007B2 (ja) | 2015-05-06 | 2016-05-02 | 固体形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021119136A JP2021119136A (ja) | 2021-08-12 |
| JP2021119136A5 true JP2021119136A5 (enExample) | 2021-11-25 |
Family
ID=53039825
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557899A Active JP7005007B2 (ja) | 2015-05-06 | 2016-05-02 | 固体形態 |
| JP2021060013A Pending JP2021119136A (ja) | 2015-05-06 | 2021-03-31 | 固体形態 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557899A Active JP7005007B2 (ja) | 2015-05-06 | 2016-05-02 | 固体形態 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10221125B2 (enExample) |
| EP (2) | EP3090998A1 (enExample) |
| JP (2) | JP7005007B2 (enExample) |
| KR (1) | KR102666390B1 (enExample) |
| CN (1) | CN107735394B (enExample) |
| AR (1) | AR104505A1 (enExample) |
| AU (1) | AU2016259054B2 (enExample) |
| BR (1) | BR112017023740B1 (enExample) |
| CA (1) | CA2984203C (enExample) |
| ES (1) | ES2969970T3 (enExample) |
| HU (1) | HUE065558T2 (enExample) |
| IL (1) | IL255194B (enExample) |
| MX (1) | MX378732B (enExample) |
| PL (1) | PL3292100T3 (enExample) |
| WO (1) | WO2016177656A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012324803B9 (en) | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| EP3307267B1 (en) | 2016-06-10 | 2019-04-10 | Oryzon Genomics, S.A. | Multiple sclerosis treatment |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| MX2018011100A (es) | 2016-03-15 | 2019-01-10 | Oryzon Genomics Sa | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. |
| US11034991B2 (en) | 2016-03-16 | 2021-06-15 | Oryzon Genomics S.A. | Methods to determine KDM1A target engagement and chemoprobes useful therefor |
| CA3071804A1 (en) | 2017-08-03 | 2019-02-07 | Oryzon Genomics, S.A. | Use of a kdm1a inhibitor in the treatment of behavior alterations |
| US20210228490A1 (en) * | 2018-05-04 | 2021-07-29 | Oryzon Genomics, S.A. | Stable pharmaceutical formulation |
| CN113631164A (zh) | 2019-03-20 | 2021-11-09 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| HRP20260110T1 (hr) | 2019-03-20 | 2026-03-13 | Oryzon Genomics, S.A. | Vafidemstat za liječenje neagresivnih simptoma graničnog poremećaja osobnosti |
| KR20210142614A (ko) * | 2019-03-25 | 2021-11-25 | 오리존 지노믹스 에스.에이. | 암 치료를 위한 이아다뎀스타트 조합물 |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| MX2023011779A (es) | 2021-04-08 | 2023-11-22 | Oryzon Genomics Sa | Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides. |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| US20250275969A1 (en) | 2022-05-09 | 2025-09-04 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006071608A2 (en) | 2004-12-16 | 2006-07-06 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog lsd1 |
| ATE476970T1 (de) | 2005-02-18 | 2010-08-15 | Universitaetsklinikum Freiburg | Kontrolle der androgen rezeptor-abhängigen gen expression durch hemmung der aminoxidase aktivität der lysin spezifischen demethylase (lsd1) |
| CN101410367A (zh) | 2005-08-10 | 2009-04-15 | 约翰·霍普金斯大学 | 多胺用在抗寄生虫与抗癌治疗学以及作为赖氨酸-特异性脱甲基酶抑制剂 |
| WO2008127734A2 (en) | 2007-04-13 | 2008-10-23 | The Johns Hopkins University | Lysine-specific demethylase inhibitors |
| EP2317992A2 (en) | 2008-07-24 | 2011-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsd1 and a mao inhibitor |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| WO2010143582A1 (ja) | 2009-06-11 | 2010-12-16 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びlsd1阻害剤 |
| US9708255B2 (en) | 2009-08-18 | 2017-07-18 | Robert A. Casero | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| JP5699152B2 (ja) | 2009-09-25 | 2015-04-08 | オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． | リジン特異的デメチラーゼ−１阻害剤およびその使用 |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| US20130197088A1 (en) | 2010-03-12 | 2013-08-01 | Robert A. Casero, JR. | Compositions and Methods for Combinations of Oligoamines with 2-Difluoromethylornithine (DFMO) |
| JP5868948B2 (ja) | 2010-04-19 | 2016-02-24 | オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． | リジン特異的脱メチル化酵素１阻害薬およびその使用 |
| ES2564352T3 (es) | 2010-04-20 | 2016-03-22 | Università Degli Studi Di Roma "La Sapienza" | Derivados de tranilcipromina como inhibidores de la histona-desmetilasa LSD1 y/o LSD2 |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| WO2012013728A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP2712316A1 (en) | 2011-02-08 | 2014-04-02 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| JP5813855B2 (ja) | 2011-03-25 | 2015-11-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | Ｌｓｄ１阻害剤としてのシクロプロピルアミン |
| WO2012156537A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| US20140329833A1 (en) | 2011-05-19 | 2014-11-06 | Oryzon Genomics, S.A | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| SG11201401066PA (en) * | 2011-10-20 | 2014-10-30 | Oryzon Genomics Sa | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| AU2012324803B9 (en) | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| US20180284095A1 (en) | 2015-06-12 | 2018-10-04 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017060319A1 (en) | 2015-10-09 | 2017-04-13 | F. Hoffmann-La Roche Ag | Gene expression biomarkers for personalized cancer care to epigenetic modifying agents |
| MX2018011100A (es) | 2016-03-15 | 2019-01-10 | Oryzon Genomics Sa | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| US11034991B2 (en) | 2016-03-16 | 2021-06-15 | Oryzon Genomics S.A. | Methods to determine KDM1A target engagement and chemoprobes useful therefor |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
-
2015
- 2015-05-06 EP EP15166641.9A patent/EP3090998A1/en not_active Ceased
-
2016
- 2016-05-02 MX MX2017014035A patent/MX378732B/es unknown
- 2016-05-02 AU AU2016259054A patent/AU2016259054B2/en active Active
- 2016-05-02 US US15/571,945 patent/US10221125B2/en active Active
- 2016-05-02 BR BR112017023740-7A patent/BR112017023740B1/pt active IP Right Grant
- 2016-05-02 CN CN201680025229.8A patent/CN107735394B/zh active Active
- 2016-05-02 KR KR1020177035160A patent/KR102666390B1/ko active Active
- 2016-05-02 PL PL16719864.7T patent/PL3292100T3/pl unknown
- 2016-05-02 ES ES16719864T patent/ES2969970T3/es active Active
- 2016-05-02 WO PCT/EP2016/059726 patent/WO2016177656A1/en not_active Ceased
- 2016-05-02 EP EP16719864.7A patent/EP3292100B1/en active Active
- 2016-05-02 HU HUE16719864A patent/HUE065558T2/hu unknown
- 2016-05-02 JP JP2017557899A patent/JP7005007B2/ja active Active
- 2016-05-02 CA CA2984203A patent/CA2984203C/en active Active
- 2016-05-03 AR ARP160101249A patent/AR104505A1/es unknown
-
2017
- 2017-10-22 IL IL255194A patent/IL255194B/en active IP Right Grant
-
2021
- 2021-03-31 JP JP2021060013A patent/JP2021119136A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021119136A5 (enExample) | ||
| JP2018516883A5 (enExample) | ||
| JPWO2022138988A5 (enExample) | ||
| CN101528762A (zh) | 5-氨基-3-(2′,3′-二-O-乙酰基-β-D-呋喃核糖基)-3H-噻唑并[4,5-D]嘧啶-2-酮的马来酸盐的结晶A和B形式 | |
| US10710961B2 (en) | Method for preparing intermediate of 4-methoxypyrrole derivative | |
| US11028069B2 (en) | Salt of substituted piperidine compound | |
| TW201514165A (zh) | Ｄ-葡萄糖醇，１-脫氧-１-（甲胺基）-，-１-（６-胺基-３，５-二氟吡啶-２-基）-８-氯-６-氟-１，４-二氫-７-（３-羥基氮雜環丁烷-１-基）-４-側氧基-３-喹啉羧酸的結晶形態與其製備程序 | |
| EA013005B1 (ru) | Производное изоксазолина и новый способ его получения | |
| CN111278808B (zh) | 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 | |
| JP2005529084A5 (enExample) | ||
| RU2451016C2 (ru) | Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида | |
| RU2007143025A (ru) | Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты | |
| CN108299279A (zh) | 取代芳基胺醇化合物及其制备方法和用途 | |
| JP7132211B2 (ja) | ３－（３，５－ジクロロ－４－ヒドロキシベンゾイル）－１，１－ジオキソ－２，３－ジヒドロ－１，３－ベンゾチアゾールの結晶形及び塩 | |
| CN1452613A (zh) | 无定形的托拉塞米变体 | |
| JPWO2002083633A1 (ja) | トシル酸スプラタスト結晶 | |
| CN1880294B (zh) | 右酮洛芬氨丁三醇的多晶型、其制备方法和包含它的组合物 | |
| US20220402861A1 (en) | A Crystalline form of (R)-terbutaline Hydrochloride | |
| CN104768927B (zh) | (3s,3s’)‑4,4’‑二硫烷二基双(3‑氨基丁烷‑1‑磺酸)合l‑赖氨酸的新的结晶相 | |
| US7943655B2 (en) | Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use | |
| CN106478603B (zh) | 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途 | |
| JPWO2021252309A5 (enExample) | ||
| CN102131506B (zh) | 盐酸格拉司琼的多晶型和其制备方法 | |
| JPWO2021252311A5 (enExample) | ||
| CN107922322B (zh) | 化合物n-(3,5-二甲基苯基)-n′-(2-三氟甲基苯基)胍的制备方法 |